Get notified when COCH files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Risk Profile Improvements

  • Material Weakness (removed) — Material weaknesses in internal controls (insufficient accounting personnel, deficient risk assessment, inadequate IT controls, missing formal policies) disclosed in baseline filing but entire controls section absent from current filing.
NASDAQ: COCH Envoy Medical, Inc. 10-Q

Envoy completes 56-patient trial enrollment, raises $27.6M; material weakness disclosures vanish

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~1 min read

Key Changes

  • high

    All 56 pivotal trial patients enrolled and activated by March 2025; first three reached 12-month follow-up milestone. FDA approval now expected H2 2027 (no panel) or H1 2028 (with panel).

    MD&A: Clinical Progress verify on EDGAR →
  • high

    February 2026 equity raise brought in $27.6M net proceeds, boosting cash from $3.7M to $25.3M. Management projects runway into Q2 2027, extendable via warrant exercises.

    MD&A: Liquidity verify on EDGAR →
  • high

    Term Loans ($25M outstanding in Q1 2025) extinguished August 2025, eliminating $495K quarterly interest expense and removing related-party debt obligation.

    MD&A: Debt Extinguishment verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.

Partner

Trade COCH commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 1, 2026 3:29 PM